IONIS HBV LRx
Alternative Names: GSK 3389404; GSK-404; IONIS-HBV-LRX; ISIS GSK6 LRxLatest Information Update: 28 Sep 2022
At a glance
- Originator Isis Pharmaceuticals
- Developer GSK
- Class Antisense elements; Antisense oligonucleotides; Antivirals
- Mechanism of Action RNA interference; Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Sep 2022 No development reported - Phase-II for Hepatitis B in China, Japan, South Korea, Philippines, Singapore, Hong Kong (SC) (NCT03020745)
- 08 Nov 2019 Efficacy, adverse events and pharmacokinetics data from a phase II trial in Hepatitis B presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2019)
- 06 Nov 2019 GlaxoSmithKline completes a phase-II clinical trials in Hepatitis B in Singapore, Philippines, South Korea, Japan, China, Hong Kong (SC) (NCT03020745)